These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: Carvedilol in heart failure. Author: Kelly DT. Journal: Cardiology; 1993; 82 Suppl 3():45-9. PubMed ID: 8106165. Abstract: Sustained oral treatment with beta blockers has been shown to improve symptoms in patients with chronic heart failure. In non-placebo-controlled trials, the administration initially of a low dose, gradually increased over a period of weeks has been demonstrated to improve both symptoms, exercise capacity and left-ventricular ejection fraction. The rationale for this treatment is the enhanced adrenergic stimulation present in heart failure which results in decreased sensitivity and density of myocardial beta-receptors. Beta blockers may decrease this pathological adrenergic drive. Carvedilol, in addition to its beta-blocking properties, is a vasodilator and is theoretically more suitable than earlier compounds of its potential to further decrease left-ventricular afterload. Recent studies have demonstrated symptomatic improvement with carvedilol in patients with heart failure, and a multicentre trial has been designed to evaluate its efficacy and safety.[Abstract] [Full Text] [Related] [New Search]